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AERITABLE COMPONENT
F VALVULAR HEART DISEASE (VHD)
he Utah Population Database is a population-based gene-
logical resource composed of Utah pioneers and their
escendants that contains electronic records of 2,237,324
ndividuals. The familial relative risk of death for age 65
ears was four times higher in first-degree relatives of those
ith aortic valve disease (Table 1) (1).
THEROSCLEROSIS, CALCIFICATION,
ND BONE FORMATION IN VALVES
alcific aortic stenosis (AS). Early lesions are similar to
therosclerosis, with prominent accumulation of “athero-
enic” lipoprotein, including low-density lipoprotein (LDL)
nd lipoprotein(a), evidence of LDL oxidation, an inflam-
atory cell infiltrate, and microscopic calcification. In late
esions, there are more prominent accumulation of lipid cells
nd extracellular matrix (Fig. 1) (2).
itral valve. Rabbits fed a 1.0% cholesterol diet showed
n increase in connective tissue and collagen formation,
ncreased myofibroblast proliferating cell nuclear antigen-
taining and alpha-actin-positive staining cells, macro-
hages, significant deposition of osteopontin, and increased
evels of osteopontin ribonucleic acid expression. Rabbits
ed cholesterol and atorvastatin showed markedly lower
therosclerotic lesions (Fig. 2) (3).
heumatic valves. Calcification within the rheumatic
alves was not seen in degenerative or normal valves.
ascular endothelial growth factor was present in areas of
nflammation. Immunohistochemistry localized osteopontin
nd osteocalcin to areas of smooth muscle cells within
icrovessels and proliferating myofibroblast, and their pro-
ein expression was upregulated in the calcified rheumatic
alves (Fig. 3) (4).
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ardiovascular magnetic resonance imaging (CMR) in
S. The intra- and interobserver variability of aortic valve
rea (AVA) by CMR ranged from0.18 to0.13 cm2 and
rom 0.11 to 0.16 cm2. Patients underwent CMR 7  5
ays after cardiac catheterization (CC; n 39); 10 8 days
fter transthoracic echocardiography (TTE; n  41); and
 5 days after transesophageal echocardiography (TEE;
 35). The sensitivity and specificity to detect AVA0.8
m2 by CC for CMR was 78% and 79%; for TTE was 74%
nd 67%, and for TEE was 70% and 70% (5).
OMMENT. There was a time delay between CMR and
ther tests, but the procedural reproducibility of CMR was
ot documented. Performance of CC may have been less
han ideal because aortic pressure was measured by “pull
ack;” also, the method of determining oxygen consumption
s not given. Sensitivity and specificity to detect AVA 1.0
m2 is not given but would have been of value to know.
here is end-systole in aortic pressure tracing to assess
VA? Animal experimental AS showed the location of end
f systolic outflow at the incisura may occur after left
entricular (LV) pressure has fallen below aortic pressure, at
imes called “hang out.” It occurs for a minuscule period of
ime (18 ms) at a time when the flow rate is very small (10
l/s). In patients, depending on whether one uses the
ressure crossover or at the incisura to calculate systolic
jection period, the flow rate and pressure gradient were
ifferent. In 38 patients, the values for AVA for the pressure
rossover and incisura methods were 0.9  0.33 versus
.88  0.36; the value for absolute difference in AVA was
ery small (0.02  0.02) (6).
OMMENT. In the example provided, the LV and aortic
ressures are less than satisfactory (Fig. 4).
-type natriuretic peptide. B-type natriuretic peptide
BNP) was regulated by systolic and diastolic load, suggest-
ng that myocardial stretch modulates BNP (7).
nduction of local angiotension II-producing system.
ngiotensin-converting enzyme (ACE) and chymase, two
ngiotensin-forming enzymes, are present in aortic valves
nd are upregulated in AS valves (8).
eights of aortic valves to severity of AS. Three hundred
wenty-four patients had “isolated” aortic valve replacement
AVR) for AS, had peak LV to systemic arterial peak
ystolic pressure gradients 10 mm Hg, and had calculated
VA. As the weights of the valves increased from 1 g to
6 g, the average peak gradient increased and AVA
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The Year in Valvular Heart Disease January 17, 2006:427–39ecreased; the r values between the valve weight to gradient
anged from 0.49 to 0.62, and to AVA ranged from 0.28
o 0.44 (9).
igure 1. (A) Potential pathways depicting calcific aortic valve disease.
etalloproteinase. (B) Histological findings in early and late lesions of calc
able 1. FRR Estimates Among the Early Age at Death Cases
Cause of Death Category Relatives, n Death
ortic valve disease (n  202)
First-degree relatives 959
Second-degree relatives 2,274
itral valve disease (n  579)
First-degree relatives 3,658
Second-degree relatives 8,384
ll valvular diseases (n  852)
First-degree relatives 4,856
Second-degree relatives 11,144
HD (n  2,717)
First-degree relatives 13,095
Second-degree relatives 25,560
p  0.0001 (significant after Bonferroni correction); †p  0.001. From Horne et a
FRR  familial relative risk; RHD  rheumatic heart disease.ubendothelial elastic lamina. In late lesion, arrow indicates elastic lamina is disp
100). From Freeman and Otto (2). Prints of figure provided by C.M. Otto,OMMENT. Peak gradients were measured from LV to
systemic” arterial pressure and not to ascending aortic
ressure; mean gradients are not presented. The r values
interleukin; TGF  transforming growth factor; and MMP  matrix
rtic valve disease. In early lesion, arrow indicates displacement of normal
served, n Deaths Expected, n
FRR (95% CI)
for Age <65 yrs
0 2.5 4.02 (1.93–7.4)*
8 7.2 1.11 (0.48–2.18)
7 16.8 2.80 (2.05–3.72)†
2 35.7 1.74 (1.33–2.23)†
1 39.0 1.82 (1.42–2.30)†
5 98.7 1.17 (0.96–1.40)
2 201.6 1.94 (1.76–2.15)†
6 317.8 1.12 (1.01–1.24)IL 
ific aos Ob
1
4
6
7
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35laced and fragmented. (Verhoeff-van Giesen stain, original magnification
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January 17, 2006:427–39 The Year in Valvular Heart Diseaseere small. The method of measurement of cardiac output
s not described. Aortic valve replacement was performed in
any patients with moderate AS, in some with mild AS,
nd in one with minimal AS (AVA 2.0 cm2)!
utcome of 622 asymptomatic adults with “hemodynam-
cally significant” AS. The authors stated, “The purpose of
he present study was to evaluate the natural history of
symptomatic, hemodynamically significant valvular
S . . .” (10). Six hundred ninety-four patients aged 40
ears with valvular AS fulfilled entry criteria; 72 patients had
VR initially, and the remaining 622 formed the study
roup. During follow-up, 297 developed symptoms but 90
30%) did not have surgery, and 325 remained asymptom-
tic but 145 (45%) had surgery. The probability of remain-
ng free of cardiac symptoms while unoperated was 82% at
ne year, 67% at two years, and 33% at five years. At 10
ears, there were six patients at risk.
OMMENT. Can one evaluate the natural history when
here were no uniform criteria by which to perform or deny
urgery in the asymptomatic and symptomatic patients? The
ncidence of performances of coronary arteriography and of
ssociated significantly obstructive coronary artery disease
CAD) in patients who were aged 72  11 years is not
igure 2. Light microscopy of rabbit mitral valves and papillary muscle. Co
12. (A) Alpha-actin immunostain, (B) RAM-11, macrophage immuno
steopontin immunostain. From Makkena et al. (3). Prints of figure provrovided. In the Otto study (11), 42% of asymptomatic Hatients subsequently underwent coronary arteriography,
nd 50% of these had significantly obstructive CAD, in-
luding left main and three-vessel CAD. In the present
tudy, were cardiac symptoms and events due to AS and/or
AD? Of interest, mortality of those undergoing surgery
ersus no surgery in those who developed symptoms was
1.7% versus 77.7%, and in those who remained asymptom-
tic 28% versus 57%; time from onset of symptoms to
urgery and from symptoms and/or surgery to death is not
rovided.
o pharmacological agents reduce progression and/or
everity of AS? Beta-blockers, ACE-I, and angiotensin re-
eptors blocks do not do so (12,13). A retrospective study
uggested statins do (13); a randomized trial was negative (14).
eyde’s syndrome. Of 3.8 million patients discharged
rom public hospitals in the Republic of Ireland, the
ncidence of gastrointestinal bleeding in the presence of AS
as 0.9% with an odds ratio of 4.5, 95% confidence interval
CI) 3.0 to 6.8, and a p value of 0.0001 (15).
ORTIC REGURGITATION (AR)
V repair (AVrep) for AR. Aortic valve repair was per-
ormed in 57% of patients undergoing surgery for AR.
diet, cholesterol, and cholesterol  atorvastatin. All frames, magnification
(C) Proliferating cell nuclear antigen, (D) Masson trichrome stain, (E)
by N.M. Rajamannan, MD.ntrolospital mortality was 3.9% (16); reoperation for recurrent
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The Year in Valvular Heart Disease January 17, 2006:427–39R was 3.3%. In patients with isolated repair, isolated root
epair, and a combination of both, at five years the incidence
f AR grade II was 19%, 16%, and 6%, respectively; the
ncidence of reoperation was 7%, 5%, and 2%, respectively.
ffectiveness of beta-blockade in experimental “chronic”
R. Thirty-eight 38 male Wistar rats were studied (17).
etoprolol treatment, compared to no treatment, resulted
n a smaller increase in LV size, prevented reduction of left
entricular ejection fraction (LVEF), increased the expres-
ion of B1-adrenoreceptor messenger ribonucleic acid, and
educed G-protein receptor kinase 2 levels. Collagen I and
II in ribonucleic acid levels were reduced. Cardiac myocyte
ypertrophy was also reduced.
ICUSPID AORTIC VALVE (BAV)
ortic root dilation. In 162 consecutive patients with
AV, age 23.6  19.8 years (18), the dimensions at the
inuses of Valsalva, sinotubular junction, and ascending
orta were increased (Table 2).
Vrep for AR. Of 132 patients with BAV AR, 57% had
igure 3. Identification of bone matrix markers in calcified human rheum
o myofibroblast staining cells (magnification 40). All others, magnifica
ncalcified degenerative mitral valve (D2). From Rajamannan et al. (4). PVrep and 43% had AVR (19). By multivariate analysis, sVrep was associated with eccentric jet direction, cusp
hickening, commissural thickening, and cusp calcification.
OMMENT. There are no data on patient outcomes at
ollow-up.
alve-sparing aortic root replacement by the remodeling
echnique: a “reasonable option?” This procedure was
erformed in 60 patients with BAV (Group A) and in 130
atients with tricuspid aortic valve (Group B) (20). Com-
aring Group A to Group B, hospital mortality was 0%
ersus 5%; at five years, freedom from AR grade2 was 4%
ersus17% (p 0.07), and freedom from reoperation was
8% versus 98% (Fig. 5).
ITRAL STENOSIS (MS)
atheter balloon commissurotomy (CBC) during
regnancy. Thirty-six patients, age 25.8  4.3 years, un-
erwent CBC at a mean gestational period of 26.5  5.3
eeks; 25 patients were in New York Heart Association
NYHA) functional class III/IV (21), 23 had a Massachu-
alves. Stains as in Figure 2. C  osteocalcin immunostain. Arrow points
10. Micro CT 3D reconstruction of calcified rheumatic valve (D1) and
of figure provided by N.M. Rajamannan, MD.atic vetts General Hospital (MGH) echocardiographic score of
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January 17, 2006:427–39 The Year in Valvular Heart Disease8, and 13 had a score 8. Fluoroscopy time was 2 min
n 8.3%, 2 to 4 in 55.6%. The procedure was successful in 35
f 36 patients with reduction of left atrial (LA), pulmonary
rtery (PA) pressures, and an increase of mitral valve area
MVA) from 0.74 to 1.59 cm2 (all p  0.001). Mitral
egurgitation (MR) increased by two grades in 19.4%; none
eeded valve surgery. There were no abortions or stillbirths;
ll children did well long-term and had normal mental
evelopment. All patients were in NYHA functional classes
and II.
ricuspid regurgitation (TR) regresses after CBC. Of 53
atients with severe MS and TR grade2, on a 1 to 3 scale,
R regressed after CBC in 51% (22). Patients in whom TR
egressed were younger and had lower incidence of atrial
brillation (AFib), higher PA pressure, higher prevalence of
unctional TR, and more severe MS (p  0.005).
igure 4. (A) Adapted from Bermejo et al. (6). Pressure tracings obtained w
mall. Both left ventricular (LV) diastolic and aortic pressure pulses look da
nd is frequently in the arch. There is a large “hang out.” (B) Simultaneous
tenosis. Note the LV diastolic pressures are not damped, and the ascendi
s very brief and minimal. The ascending aortic pressure shows the anac
irector, Interventional and Alex Durairaj, MD, Director, Cardiac Cathe
VAI  aortic valve area index; SEP  systolic ejection period.
able 2. Aortic Dimensions of Different Levels With BAVs
nd Controls
Variable
Patients With BAVs
(n  162)
Controls
(n  162)
nnulus (mm/m2) 15.4  4.7 14.4  4
inuses of Valsalva (mm/m2) 22  6.5* 19.5  5.1
inotubular junction (mm/m2) 19.5  6.3† 16.7  4.1
scending aorta (mm/m2) 23.7  7.3† 18.6  4.7
ortic arch (mm/m2) 15.1  4.7 14.4  3.8
escending aorta (mm/m2) 12.4  3.2 12.3  2.9
bdominal aorta (mm/m2) 10.2  3 10.5  2.5
alues are expressed as mean  SD. *p  0.01; †p  0.001. From Cecconi M et al.r
18).
BAV  bicuspid aortic valve.etter LV function with chordal preservation at time of
VR for rheumatic mitral valve disease (MVD). Pa-
ients who had complete chordal preservation (n  250) on
ollow-up had smaller LV end-diastolic and end-systolic
olumes and higher LVEF than those who had complete
xcision of subvalvular apparatus or who had preservation
nly of posterior chordopapillary apparatus (23). The last
roup had better LVEF than those who had complete
xcision of subvalvular apparatus.
agnetic resonance imaging (MRI) for estimation of
everity of MS. In 17 patients the MVA by MRI showed
“good” correlation with CC (n  17; r  0.89) and a
easonable one with TTE (n  20; r  0.81) (24).
redicting mean PA wedge pressure from Doppler
ecording. Two-dimensional Doppler and tissue Dopp-
er imaging were performed simultaneously with right
eart catheterization in 51 consecutive patients (aged 64
11 years) with MVD: 35 with moderately severe to
evere MR and 16 with moderate to severe MS (25). The
atio of isovolumic relaxation time (IVRT) to TE-Ea for
R and for MS had r values of 0.92 and 0.88,
espectively, both p  0.001. The ratio of IVRT to  had
values of 0.74 for MR and 0.85 for MS (both p 
.001).
OMMENT. In patients with MR, IVRT/TE-Ea of15, the
ean PA wedge pressure ranged from about 15 to 38 mm
g, and in MS with IVRT/TE-Ea of4.5, mean PA wedge
ressure ranged from about 15 to 36 mm Hg. For MR for
n IVRT/ of about 1.2 to 1.8, the mean PA wedge pressure
-F double lumen catheter. Both lumens, especially the aortic one, are very
. Lumen of the aortic opening is about 15 to 20 cm from the LV opening
nd aortic pressure from two separate catheters in patient with severe aortic
rtic catheter, which is about 1 to 2 cm above the valve, shows “hang out”
notch” on the ascending limb. Tracings provided by Anil Mehra, MD,
tion Laboratory, LACUSC Medical Center. AVA  aortic valve area;ith 8
mped
LV a
ng ao
rotic “anged from about 10 to 25 mm Hg, and in MS for an
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The Year in Valvular Heart Disease January 17, 2006:427–39VRT/ of 1.2 to 1.6, mean PA wedge ranged from 16 to 32
m Hg. All cited values are from a review of their Figures
and 4.
ITRAL REGURGITATION
cute pulmonary edema (APE) with ischemic mitral
egurgitation (IMR). Of 28 patients aged 65  11 years
ith IMR, those with episodes of APE (Group I) were
ompared to 46 patients without history of APE, all of
hom had previous acute myocardial infarction and LV
ystolic dysfunction (26). On exercise, patients in Group I
ad less reduction of LV end-systolic volume (p  0.06),
ess reduction of LV wall motion index (p  0.02), and
reater increases of tenting area, regurgitant volume, effec-
ive regurgitant orifice area, and tricuspid pressure gradient
all p  0.001).
Fib after MV repair (MVrep)/MVR is common. Of
62 patients in sinus rhythm and with no previous history of
Fib who had MVrep/MVR, 69 (9%) developed early AFib
ithout recurrence (Group I); 67 (8.8%) had early AFib and
lso had late AFib at 10 years (Group II); and 44 (5.8%)
eveloped only late new AFib (Group III) (27). Group I
atients were characterized by angina class and lower
VEF, but not by LA enlargement (LAE), which was
iagnosed as LA dimension 50 mm. Sixty-seven of 136
49%) of those with early AFib developed late AFib. Large
A size independently predicted early AFib (p  0.01) and
ate AFib (p  0.003). Postoperative AFib was associated
ith an increased higher risk of stroke or heart failure (HF)
adjusted risk ratio 1.46; 95% CI 1.04 to 2.05; p  0.03).
he authors concluded that for patients with LA enlarge-
ent, “. . . surgery may be considered earlier in the course of
he disease.”
OMMENT. This was an interesting study. Patients with
ate AFib had higher systolic and diastolic blood pressure.
nly 10% of those with late AFib had an “ischemic”
igure 5. (A) Actuarial freedom from aortic regurgitation grade II after
rom reoperation. From Aicher et al. (20).tiology; 31% had MVR, of whom 47% had mechanical salves; there is no information on preservation of chordo-
apillary apparatus (see the previous text); also, was rheu-
atic another etiology? Left atrial dimensions were not
orrected for body size; the American Society of Echocar-
iography recommends maximum LA diameter in the A-P
iew 2.0 cm/m2 (36 ml/m2) as normal. The exact
umber of patients who initially had LAE can be calculated.
t is stated that of patients with LAE, 20% (n  136)
eveloped early AFib; thus about 680 patients probably had
AE and 111 had late AFib, which is 16% (111 of 680).
urgery in 680 patients to save 111 from having late AFib
uts 569 patients at risk for mortality and morbidity both
arly and late after surgery. Also, the incidence of late AFib
as about 2% per year (12% at 5 years, 19% at 10 years).
ggressive treatment of co-morbid conditions and antico-
gulation for late AFib is important but is not described. In
he Atrial Fibrillation Follow-up Investigation of Rhythm
anagement study, larger LA diameters were associated
ith recurrent AFib (p  0.01) but not with stroke (p 
.44) (28); patients had warfarin with an international
ormalized ratio (INR) goal of 2 to 3. Moreover, in the
urrent era catheter ablation of AFib is possible.
symptomatic patients with MR. Four hundred fifty-six
456) asymptomatic patients (LVEF 0.70  0.08%), 63%
en, with organic MR were studied (29). The estimated
ve-year survival (SE) of death from any cause, death
rom cardiac causes, and cardiac events (death from cardiac
auses, HF, or new AFib) with medical management were
2 3%, 14 3%, and 33 3%, respectively. Independent
eterminants of survival were increasing age, the presence of
iabetes, and increasing effective regurgitant orifice (ERO).
hose with ERO 40 mm2 when compared to those with
RO of 20 mm2 had increased event rates. Two hundred
hirty-two patients had surgery: 94 for symptoms, 91 for
cho parameters, and 47 by physician and patient prefer-
nces. Those who had surgery had better outcomes. The
uthors concluded, “patients with an ERO of 40 mm2
c root remodeling in bicuspid and tricuspid valves. (B) Actuarial freedomhould promptly be considered for cardiac surgery.”
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January 17, 2006:427–39 The Year in Valvular Heart DiseaseOMMENT. The accompanying editorial (30) pointed out
ome of the limitations with regard to the conclusion and
ecommended a randomized trial of surgery on the basis of
RO. Earlier, Robert L. Frye, the most senior cardiologist
t the Mayo Clinic and past president of the American
ollege of Cardiology (ACC), had recommended a ran-
omized trial of surgery in asymptomatic patients with
evere MR (31). The cardiac causes of death averaged 3%
er year, but was MR the cause of death? Patients’ age was
3  14 years, but there are no data on the percentage of
atients who at entry had coronary arteriography and
ignificantly obstructive CAD. Important details of “medi-
al management,” for example, actual treatment and effec-
iveness of therapy of co-morbid conditions such as hyper-
ension, were not provided. Twenty percent of those who
ad MVR/MVrep had surgery by physician and patient
references.
RICUSPID REGURGITATION
ulmonary thromboendarterectomy (PTE) reduces/
bolishes pulmonary hypertension (PHTN) and severe
R. Twenty-seven patients with severe TR underwent
TE; TR resolved in 19 (70%) (Group A) and was
ersistent in 8 (30%) (Group B) (32). By echo/Doppler,
roup A patients had greater reduction of PA systolic
ressure than Group B (85 16 mm Hg to 36 8 mm Hg
s. 87  29 mm Hg to 55  26) (p  0.019) (Fig. 6). By
ardiac catheterization data, the fall in PA systolic pressure
as also greater in Group A than in Group B (37  16 mm
g vs. 16  13 mm Hg; p  0.004). No difference was
bserved in tricuspid annular diameter, apical displacement
f the tricuspid valve, or other features between the two
roups. The authors concluded, “After significant PA pres-
ure reduction by PTE, severe functional TR with a dilated
nnulus may improve without annuloplasty despite dilated
ricuspid annulus diameters.”
OMMENT. These findings are impressive and suggest an
mportant role for PTE early when TR is mild or even
arlier when PHTN is moderate or severe.
igure 6. Preoperative and postoperative severity of pulmonary hyperten-
ion (by echocardiographic measurements) stratified by resolved (open
ars) or persistent (solid bars) tricuspid regurgitation before and afterh
ulmonary thromboendarterectomy (PTE). PAS  pulmonary artery
ystolic pressure. From Sadeghi et al. (32).amage to tricuspid valve (TV) by permanent pacemaker
PPM) or implantable cardioverter-defibrillator (ICD)
ead. Of 41 patients, 7 had perforation of TV by PPM or
CD leads, 4 had lead enlargement of the TV, 16 had lead
mpingement of TV leaflets, and 14 had lead adherents to
V (33). The septal leaflet was perforated in six of seven
ases. Transthoracic echocardiography diagnosed 12% of
atients with TV leaflet perforation or impingement, and
3% of patients were diagnosed as having severe TR.
ransesophageal echocardiography showed TV malfunction
ue to PPM lead in 45% and severe TR in all. Time from
PM implantation to operation was 72 months (range 2 to
28 months).
V tethering predicts residual TR after tricuspid annu-
oplasty. Two hundred sixteen patients with functional TR
ad two-dimensional TTE before and 5  4 days after TV
nnuloplasty and left heart valve surgery (34). Multivariate
nalysis showed age, tethering distance, and severity of
reoperative TR (all p  0.001) were independent predic-
ors of residual TR. The sensitivity and specificity in
redicting residual TR after surgery were 86% and 80% for
ethering distances 0.76 cm and 82% and 84% for teth-
ring areas 1.63 cm2.
R due to flail TV leaflets: medical and surgical out-
ome. In 60 patients with TR due to “flail leaflets” (35), the
ost common cause was trauma (n 37), of which 19 were
ue to blunt trauma and 18 to iatrogenic chordal severing,
ost from RV biopsy. Survival at 10 years was 61  10%.
ricuspid surgery was performed in 33 patients at five years
n 55  7%. The composite event rate of dyspnea or HF,
ew AFib, cardiac surgery, or death at 10 years was 75
13%.
PORTS ACTIVITIES FOR PATIENTS WITH VHD
he ACC Bethesda Conference has made suggestions (36).
NFECTIVE ENDOCARDITIS (IE)
mericanHeart Association (AHA) scientific statement. De-
cribes recommendations for the diagnosis, anti-microbial
herapy, and management of IE (37).
olecular approach to diagnose IE. Broad-range poly-
erase chain reaction (PCR) targeting bacterial and fungal
DNA followed by direct sequencing was applied to 52
xcised heart valves with suspected IE and from 16 patients
ithout any sign of IE. The sensitivity, specificity, and the
ositive and negative predictive values for the bacterial
road-range PCR were 41.2%, 100%, 100%, and 34.8%
38).
OMMENT. The accompanying editorial (39) describes the
trength and weakness of this study.
aximum of three TEEs is necessary for diagnosis. Two
undred sixty-two patients with 266 episodes of suspected
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The Year in Valvular Heart Disease January 17, 2006:427–39E were referred for TTE/TEE (40). Of these, 47.8% had
efinite IE, 30.4% had possible IE, and in 21.8% the
iagnosis was rejected. Diagnostic findings from TTE and
EE in the first examination were 21.2% and 68.5%,
espectively; reclassifications after the second examination
ere 13.5% and 46.9%, respectively, and after the third
xamination were 7.5% and 20%, respectively. After the
hird examination, the yield was zero.
ntibiotic prophylaxis: better education needed. The
uro Heart Survey on Valvular Heart Disease (41) docu-
ented antibiotic treatment was started before blood cul-
ures were obtained in 71% of patients with IE. Fifty
ercent of those with native VHD had been educated in
ndocarditis prophylaxis, and 33% regularly attended dental
ollow-up. Only 50% of patients with IE who had had a
rocedure at risk during the preceding year had received
dequate prophylaxis. The authors concluded: “. . . Im-
rovement of patient management through education and
mplementation of guidelines . . .” is justified.
oor mid-term outcome for medically successfully
reated IE. Sixty-seven of 151 (44%) patients with IE were
uccessfully treated (42). Thirty-five underwent late surgery
o correct sequelae of the infection, and 21 of 35 (68%) of
hose who underwent late surgery died during follow-up.
orty patients (60%) died from cardiovascular causes as a
irect consequence of IE or because of worsening of the
nderlying cardiac disease. Survival rates without cardiac
urgery at 1, 3, and 5 years were 54%, 29%, and 20%,
espectively.
ong-term results of MVrep. Thirty-seven consecutive
atients (43) underwent MVrep in “active endocarditis”
sing Carpentier’s techniques between 1989 and 1994;
perative mortality was one (3%), and one patient had
eoperation for pericardial patch dehiscence. At 10 years,
urvival was 80% and freedom from MV reoperation was
1%.
MVrep versus MVR: 154 patients underwent surgery
etween 1980 and 1996 (44); 63% had MVR and 37% had
Vrep. The 30-day mortality was 3.2%; 4% after MVR and
% after MVrep. Survival at 1, 5, and 10 years was 93%,
1%, and 61%, respectively; survival at 10 years tended to be
etter with MVrep (p 0.15). Patients who had undergone
Vrep were less frequently in NYHA functional classes
II/IV (0% vs. 29%; p  0.002), had a lower incidence of
Fib (29% vs. 47%; p  0.04), tended to have less dyspnea
20% vs. 38%; p  0.07), and needed reoperation less
requently (1.8% vs. 6.5%).
ryopreserved aortic valve homograft for active aortic
E. From 1992 to 2002 (45), 104 patients had cryopre-
erved aortic valve homograft; 73% had IE of native valve,
7% for prosthetic valve; 80% had isolated aortic IE.
ospital mortality was 5%. At 10 years, actuarial survival
ate was 83%, freedom from reoperation was 76%, and
reedom from recurrent IE was 93%. There were no
hromboembolic complications.
n
vNTICOAGULANT AND ANTI PLATELET THERAPY
arfarin dose requirement is related to gene encoding
itamin K epoxide reductase complex 1 (VKORC1). Ten
ommon non-coding VKORC1 single-nucleotide polymor-
hisms were identified and five major haplotypes were
nferred. A low-dose haplotype group (A) and a high-dose
aplotype group (B) were identified (46). The maintenance
ose (mean  SE) of warfarin differed among the three
aplotype group combinations (p  0.001) (Fig. 7). Vita-
in K epoxide reductase complex 1 haplotype Groups A
nd B explained approximately 25% of the variance in dose.
he frequency of Group A haplotypes predictive of lower
arfarin dose was higher in the Asian Americans (89%) and
ower in the African Americans (14%) than in the European
mericans (37%) (p  0.001 for both comparisons). The
roup distribution (A or B) was also different between these
opulations. Thus, the molecular mechanisms of warfarin
ose response appear to be regulated at the transcriptional
evel.
ntiplatelet plus moderate-intensity anticoagulation is
he most effective? The National Study for Prevention of
mbolism in Atrial Fibrillation, a prospective, randomized,
pen-label study, was performed in 13 hospitals (47).
atients with chronic or paroxysmal AFib were included;
hose at low risk were excluded. At high risk were patients
ith MS with or without prior embolism. These patients
ere randomized to anticoagulation with acenocoumarol
international normalized ratio [INR] range 2 to 3) or a
ombination of trifusal 600 mg (equivalent to aspirin 300
g) and INR 1.4 to 2.4. Primary outcome was a composite
f vascular death, transient ischemic attack, and non-fatal
troke or systemic embolism. The combined therapy group
ad fewer primary events, a log hazard ratio of 0.51, a 95%
I 0.27 to 0.96, and a p value of 0.03.
OMMENT. The accompanying editorial cautioned that the
uthors’ conclusion that in the combination therapy the
igure 7. Mean warfarin doses according to VKORC1 haplotype combi-
ation (A/A, A/B, or B/B) in all patients and in those with wild-type and
ariant CYP2C9. From Reider et al. (46).
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January 17, 2006:427–39 The Year in Valvular Heart Diseaseower limit of an INR of two is the safe limit is premature
48).
spirin or warfarin after AVR with biological prosthetic
eart valve (PHV) Patients undergoing AVR with biolog-
cal PHV received warfarin (n  41, INR between 2 and 3)
r aspirin 100 mg/day (n  108) by surgeon’s choice (49).
uring the first three months, there was no statistically
ignificant difference between the two groups with regard to
erebral ischemic events, major bleeding events, stroke-free
ntervals, and overall survival.
Between 1993 and 2000, 1,151 patients underwent AVR
ith bioprosthesis. By surgeon preference, 624 had early
ostoperative anticoagulation (AC) and 529 did not
AC) (50). Operative mortality was 4.1%. Postoperative
erebrovascular accident occurred in 2.4% of the AC
roup and in 1.9% of the AC group. The incidence of
erebral events at 30 days in the AC group was 1.5%.
he incidence of re-exploration for bleeding in the AC
roup was 5.0% and in the AC group was 7.4% (p 
.085).
OMMENT. Seventy-eight percent of patients in the AC
roup received antiplatelet therapy. Thus, both of the above
tudies did not evaluate the role of antiplatelet therapy
ersus placebo.
ERCUTANEOUS HEART VALVE PROCEDURES
ercutaneous mitral annuloplasty (PMA) for MR in
xperimental HF (51). STUDY 1. Percutaneous mitral an-
uloplasty, using a novel annuloplasty device with two
nchors, reduced annular dimension and severity of MR at
aseline and after phenylephrine infusion to increase after-
oad. Pressure volume analysis demonstrated no acute im-
airment of LV function.
TUDY 2. Seven animals were studied four weeks after device
lacement for HF. The mitral annulus decreased from
.75  0.08 to 3.37  0.23 (p  0.05), and the severity of
R was reduced (MR jet area/LA area from 0.33 0.03 to
.11  0.04; p  0.05).
ociety of Thoracic Surgeons (STS)/American Associa-
ion for Thoracic Surgery/Society for Cardiovascular
ngiography and Interventions position statement
52). The recommendations were endorsed by the ACC
nd AHA.
PECIAL SURGICAL SITUATIONS
imited durability of valve repair in patients with previ-
us mediastinal radiation therapy. Twenty-two patients
ge 61 14 years underwent valve repair, 15 9 years after
ediastinal radiation therapy (53). Follow-up was 3.7 3.3
ears. “Early” mortality was 14%. Of 19 early survivors,
verall survival, freedom from cardiac death, and freedom
rom valve reoperation or cardiac transplantation at five
ears were 66%, 85%, and 88%, respectively.
furgery in octogenarians. Aortic valve replacement for
evere AS  coronary artery bypass grafting (CABG): One
undred fifteen patients aged 82.3  2.1 years underwent
VR (62%) or AVR CABG (38%). Aortic valve area was
.62  0.15 cm2 (54). Hospital mortality was 8.5%. The
ve-year survival was 69.4%. At five years the survival for
atients with bioprosthesis was 81.7% versus 56.7% with a
echanical valve (p  0.02). Predictors of late mortality
ere LVEF (p  0.01), preoperative HF (p  0.03), and
he type of prosthesis (p  0.03). Preoperatively, 79% were
n NYHA functional classes III to IV. Postoperatively, 94%
ere in classes I to II.
Valve surgery CABG: In 405 patients, several different
rocedures were performed (55). “Early” mortality was 6.4%
nd ranged from 0% to 10%; it was 4.3% for AVR and 8.2%
or AVR  CABG; 5.7%. for MVR/MVrep  CABG. At
ve years, survival after AVR was 66  5%; after MV
urgery, 68  9% (p  0.12). Concomitant CABG did not
ffect late survival. Independent predictors of late death
ere age 85 years and LVEF 0.40. At a median
ollow-up of two years, NYHA functional class was im-
roved: preoperative 78% classes II to IV and 18% class I;
ostoperative 72% class I and 17% class II.
Surgery for isolated non-rheumatic MR: Fifty-nine pa-
ients, age 80 years or older (82  2 years), had first-time
Vrep (n  46) or MVR (n  13). The etiology was
degenerative” in 95% (56). Operative mortality was 1.7%.
he five-year survival was 61%. Preoperatively, 79% were in
YHA functional classes III/IV; postoperatively, 78% were
n NYHA functional classes I/II.
mproved patient outcomes with hybrid approach.
wenty-six patients, median age 72 years (range 53 to 91
ears) had percutaneous coronary intervention and within a
edian of 5 days (range 0 to 14 days) underwent primary or
eoperative valve surgery (57). Patients were at high risk
ith an expected STS-predicted mortality of 22%. With the
ybrid approach, the operative mortality was 3.8% and the
edian blood loss 900 ml, and 22 patients (85%) required
lood transfusions. Survival rates at one, three, and five
ears were 78%, 56%, and 44%, respectively.
uro score for predicting late mortality. One thousand
ne hundred five operative survivors who had undergone
solated valve surgery  CABG were studied (58); the
ve-year mortality (by Euro score) is shown in Table 3.
perative mortality of MR surgery with LVEF
0.30. An STS database of 14,582 patients showed oper-
tive (30-day) mortality for patients with LVEF 0.30
able 3. Survival After Valve Surgery  CABG
Standard Euro Score 5-Year Survival*†
5 90.0  2.3%
5 to 8 85.1  2.3%
8 to 11 64.8  3.3%
11 55.1  3.7%
p  0.001, log rank test with adjustment for trend; †of operative survivors. Adapted
rom Toumpoulis IK et al. (58).
CABG  coronary artery bypass grafting.
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ersus 3.1% (p  0.001). Low LVEF was not a significant
actor for mortality after controlling for other factors (59).
n patients with LVEF 0.30 versus 0.30, mortality after
Vrep was 1.4% and 1.53%, respectively, and after MVR
as 7.69% and 10.18%, respectively.
ROSTHETIC HEART VALVES
tarr-Edwards PHV is durable for more than 40
ears. Since 1960, the Starr-Edwards valve has been used
n 3,653 of 8,300 PHVs that were inserted by Starr and his
olleagues. The original models had “some engineering”
lterations up to 1964. In 1965, the models A1200/A1260
nd M6120, called “extended-cloth prosthesis,” have been
irtually unchanged and have been used continuously since
hat time to present (called “Current”). Actuarial analysis
hows survival rates at 10, 20, and 30 years for AVR were
3%, 23%, and 8%, respectively, and for MVR were 51%,
3%, and 8%, respectively; for AVR, the 40-year survival
as 4%. The standard error for all these values was 1%.
here have been no deaths from structural valve deteriora-
ion (SVD) among patients with the “current” valves. The
urvival and incidence of thromboembolism with “current”
alve are shown in Figure 8 (60).
igh-temperature-fixed (HTF) bioprosthesis in the
oung. From January 1991 to September 1998, 50 young
atients (ages range 7 months to 35 years; 22.7  6.8 years)
nderwent single HTF bioprostheses in two hospitals (Paris
nd Ho Chi Minh City) based on social, medical, and
eographical contraindications to anticoagulants. At nine
ears the actuarial survival was 95  3.6%, and freedom
rom reoperation was 87.6  7.1% (61); 91.7  8% after
VR and 80%  12.6 after MVR.
OMMENT. Does HTF represent another important aspect
f bioprosthetic preparation? HTF at 30° to 50°C (“Thermoigure 8. (A) Actuarial survival curves after aortic valve regurgitation (AVR) an
B) Kaplan-Meier (KM) actuarial and actual freedom from thromboembolismix”) is used for preparation of the Edwards PERIMOUNT
AGNA valve.
VD of St. Jude Toronto stentless porcine valve. At 5
nd 10 years, the actuarial survival rates were 89.2% and
8%, respectively, and the rates of actuarial freedom from
VD were 98.8% and 77.9%, respectively (62).
OMMENT. The rate of SVD at 10 years is similar to that
een with stented porcine valves (63).
ow rate of use of bioprostheses for AVR in patients>65
ears? Eighty thousand four hundred seventy patients aged
65 years undergoing AVR during 1999 to 2001 were
dentified from 1,045 U.S. hospitals’ Medicare Part A files
64). Use of bioprostheses increased from 28% in the first
ecile to 68% in the10th decile of hospital volumes. Bio-
rosthetic valve use increased (p 0.001) from 44% in 1999
o 52% in 2001, and with age, from 36% in patients aged 65
o 69 years and to 60% in patients age 90 years.
OMMENT. The only data from randomized trials showing
he very low rate of SVD after bioprosthetic AVR in those
ge 65 years is from the Veterans Administration trial
hose 18-year (mean 15 years) follow-up data was pub-
ished in the Journal of the American College of Cardiology in
ctober 2000 (65). Also see discussion of surgery in
ctogenarians in the preceding text. It would be of interest
o have similar data for 2004 to 2005.
omograft replacement of the mitral valve. The opera-
ive mortality in 108 patients was 3.8%. The estimate
“actual”) of reoperation was 19% at eight years; 80% of
eoperations were due to SVD (66). At eight years, the
urvival was 80  6%; freedom from cardiac events (cardiac
eaths and reoperation) was 71  6%. There were 5
eoperations within 3 months and 10 late reoperations.
perative mortality for replacing mitral PHV. Operative
ortality was 4.7% (5 of 106 patients) (67). Multivariate
nalysis showed prior myocardial infarction and “non-d mitral valve regurgitation (MVR) in the “current” Starr-Edwards valves.
after AVR and MVR with “current” valve. From Gao et al. (60).
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January 17, 2006:427–39 The Year in Valvular Heart Diseaselective” surgical status were statistically significant predic-
ors of mortality.
emodynamic performance of various PHVs. Carpentier-
dwards pericardial (CEP; PERIMOUNT) versus
edtronic Mosaic (MM) Porcine (MMP). 1) An in vitro
tudy of transvalvular resistance versus flow rate of 2 to
7 l/min in valve sizes 21, 23, and 25 MMP had lower
esistance than the CEP at low flow rates (3 l/min), after
hich the MMP showed steep increases in resistance, and
t flow rates of 4 l/min the CEP had much lower rates of
esistance (Fig. 9) (68). 2) A prospective randomized trial of
00 patients. Prosthetic heart valve areas of the Perimount
ere larger than those ofMMP in the 23 and 25 aortic annulus
iameter (71) (Table 4).
A comparison of four supra-annular bioprosthesis in
atients with small aortic annulus. A comparison of the CE
ericardial (Magna) to the CE Pericardial (Perimount),
MP, and Soprano valves in the 18- to 20-mm annulus
iameter showed there was no statistically significant dif-
erence in valve areas. In the 21- to 23-mm annulus
iameter the CE-Magna had the best hemodynamics (72)
Table 5).
igure 9. An in vitro study of transvalvular resistance versus flow rate of 2
nd Carpentier Edwards Pericardial (Perimount valves) (EP). Adapted from
.9 (SD) l/min/m2. Translating that to cardiac output in (l/min) in humans
f 1.5, 1.75, and 2.0 cm2) shows the normal cardiac outputs range from
ericardial clearly offers much lower resistance. Cardiac indexes in normals
hat in vitro studies of prostetic heart valve evaluate flow rates that are ap
able 4. Prospective Randomized Trial of CEP (Perimount)
ersus MMP Valve
Aortic Annulus
Diameter
(mm)
PHV Area Index (cm2/m2)
MMP Valve CEP Valve
21 0.70  0.04 0.74  0.07
23 0.74  0.06 0.79  0.08*
25 0.80  0.09 0.85  0.09*
27 0.88  0.10 0.93  0.08
p  0.05. The PHV index was obtained by echocardiography/Doppler at follow-up
isits 438  352 days (range 180 to 1,133). Adapted from Walther T et al. (71).
CEP  Carpentier-Edwards pericardial; MMP  Medtronic Mosaic porcine;
HV  prosthetic heart valve.
(emodynamic performance of other PHVs. Nineteen-mm
MP has a high incidence of mismatch:
In 81 consecutive patients (69 female), mean age 78.0 
.6% moderate valve prosthesis-patient mismatch (VP-PM)
defined as valve areas 0.65 to 0.8 cm2/m2) occurred in
9.4% and severe VP-PM (valve areas 0.65 cm2/m2)
ccurred in 50.6% (73). The 30-day mortality was 9.9%, and
urvival at 1 and 2 years was 78.5  4.6% and 69.1  5.5%,
espectively.
Bileaflet mechanical PHVs valve sizes in 21-mm valve
older. In an in vitro model, at flow rates of 4 l/min, the
t. Jude Medical Regent-19 and the Sorin Bicarbon Slim
ine had larger effective valve orifice areas than the ATS
8-mm, On-X 19-mm and Carbomedics Top Hat
0.005) (74).
alve prosthesis-patient mismatch. Effect of MVR on
A hypertension: Of 56 patients with “normally” function-
ng mitral PHV (75), 30 patients (54%) had PA hyperten-
ion, defined as systolic PA pressure 40 mm Hg, and 40
atients (71%) had VP-PM, defined as prosthetic MVA
1.2 cm2/m2. There was a “significant” correlation (r 
.64) between systolic PA pressure and prosthetic MVA.
he systolic PA pressure in those with VP-PM was signif-
l/min in valve sizes 21, 23, and 25 Medtronic Mosaic Porcine valve (MM)
hnel et al. (68). Cardiac index in two studies of normal humans was 3.6 
mall, moderate, or large size body surface areas (body surface areas [BSAs]
o 9.0 l/min. At these flow rates (shaded areas) the Carpentier Edwards
rom Barratt-Boyes and Wood (69) and Ehsani et al. (70). It is important
iate for normals.
able 5. Hemodynamic Comparison for Four Bioprosthesis
or Complete Supra-Annular Position
Mean AVG PHV Area
(mm Hg) p Value cm2/m2 p Values
AGNA 8.2  4.7 — 1.17  0.27 —
ERIMOUNT 10.6  3.7 0.023 0.94  0.36 0.01
OSAIC 15.1  5.6 0.001 0.83  0.23 0.001
OPRANO 12.7  4.6 0.009 0.87  0.20 0.004
values are for CE Magna vs. the other valves. Adapted from Botzenhardt F et al.to 7
Kue
with s
4.1 t72).
AVG  aortic valve gradient; PHV  prosthetic heart valve.
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The Year in Valvular Heart Disease January 17, 2006:427–39cantly higher than in those without VP-PM, 46  8 mm
g versus 34  8 mm Hg (p  0.001). In multivariate
nalysis, prosthetic MVA was the strongest predictor of
ystolic PA pressure. The authors concluded that persistent
A hypertension is frequent after MVR and is strongly
ssociated with the presence of VP-PM.
OMMENT. The accompanying editorial describes some of
he limitations of the study (76).
Moderate/severe VP-PM is associated with less LV mass
egression. Patients with moderate/severe VP-PM (PHV
rea 0.9 cm2/m2) had less LV mass regression after AVR
ompared to those with mild VP-PM (PHV area 0.9
m2/m2) 48  47 g versus 77  49 g (p  0.002) (77). The
ther independent predictors of greater LV mass regression
ere female gender and higher preoperative LV mass.
eprint requests and correspondence: Dr. Shahbudin H. Ra-
imtoola, Distinguished Professor, University of Southern Cali-
ornia, 2025 Zonal Avenue, Los Angeles, California 90033.
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